(Q34484450)

English

RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Fiona Garner

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Maysoun Shomali

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Dotty Paquin

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

C Richard Lyttle

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Gary Hattersley

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

9 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Anti-Cancer Drugs

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

948-956

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

6 July 2018

Use of SERMs for treatment in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

6 July 2018

Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

6 July 2018

The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

6 July 2018

Estrogen receptors and human disease: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

6 July 2018

Estrogen and progesterone in normal mammary gland development and in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

6 July 2018

The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

6 July 2018

Estrogen receptors in resistance to hormone therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

6 July 2018

SERMs for the treatment and prevention of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

6 July 2018

Estrogen-related receptor alpha as a therapeutic target in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

6 July 2018

Estrogen receptors as therapeutic targets in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

6 July 2018

Estrogen carcinogenesis in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

6 July 2018

Steroid hormone receptor signaling in tumorigenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

6 July 2018

Hormone- and chemotherapy-induced bone loss in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

6 July 2018

Connections and regulation of the human estrogen receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

6 July 2018

The steroid and thyroid hormone receptor superfamily

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

6 July 2018

The ovariectomized rat model of postmenopausal bone loss

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

6 July 2018

Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

27 October 2018

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4560273

27 October 2018

Chemoprevention of breast cancer with selective oestrogen-receptor modulators

1 reference

https://pubmed.ncbi.nlm.nih.gov/26164151

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/CAD.0000000000000271

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34484450&oldid=1953319691"